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Onset of Experimental Severe Cardiac Fibrosis Is Mediated
by Overexpression of Angiotensin-Converting Enzyme 2
Rachel Masson, Stuart A. Nicklin, Margaret Anne Craig, Martin McBride, Kirsten Gilday,
Paul Gregorevic, James M. Allen, Jeffrey S. Chamberlain, Godfrey Smith, Delyth Graham,
Anna F. Dominiczak, Claudio Napoli, Andrew H. Baker
Abstract—Angiotensin-converting enzyme (ACE) 2 is a recently identified homologue of ACE. There is great interest in
the therapeutic benefit for ACE2 overexpression in the heart. However, the role of ACE2 in the regulation of cardiac
structure and function, as well as maintenance of systemic blood pressure, remains poorly understood. In cell culture,
ACE2 overexpression led to markedly increased myocyte volume, assessed in primary rabbit myocytes. To assess ACE2
function in vivo, we used a recombinant adeno-associated virus 6 delivery system to provide 11-week overexpression
of ACE2 in the myocardium of stroke-prone spontaneously hypertensive rats. ACE2, as well as the ACE inhibitor
enalapril, significantly reduced systolic blood pressure. However, in the heart, ACE2 overexpression resulted in cardiac
fibrosis, as assessed by histological analysis with concomitant deficits in ejection fraction and fractional shortening
measured by echocardiography. Furthermore, global gene expression profiling demonstrated the activation of profibrotic
pathways in the heart mediated by ACE2 gene delivery. This study demonstrates that sustained overexpression of ACE2
in the heart in vivo leads to the onset of severe fibrosis. (Hypertension. 2009;53:694-700.)
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Overactivity of the renin-angiotensin (Ang) system playsa fundamental role in the pathophysiology of hyperten-
sion and progression of heart failure.1 Ang-converting en-
zyme (ACE) 2 is a recently identified homologue of ACE,
and their catalytic domains share 42% amino acid identity.2–4
ACE2 expression is restricted to the heart, kidney, and
testis.2,5 After myocardial infarction, increased ACE2 expres-
sion in the heart localized to vascular endothelium, smooth
muscle, and cardiomyocytes in both rats and humans.6 Unlike
ACE, ACE2 functions as a carboxypeptidase rather than a
dipeptidyl carboxypeptidase5 and counterbalances the vaso-
pressor effects of ACE.7 ACE2 primarily hydrolyzes Ang II
and, less efficiently, Ang I,2 resulting in Ang 1-7 and Ang
1-9. Ang 1-9 is further hydrolyzed to Ang 1-7 by the actions
of ACE.5 ACE inhibitors and Ang II receptor blockers are
effective drugs for the treatment of cardiovascular diseases,
as a result of blocking the vasoconstrictor, hypertrophic, and
proinflammatory actions of Ang II.8–11 Thus, ACE2 may play
a pivotal role in the renin-Ang system by reducing concen-
trations of Ang II and raising levels of Ang 1-7.12,13 There-
fore, manipulation of ACE2 activity has potential therapeutic
use. However, ACE2 knockout mice have been associated
with severe contractile dysfunction14 or, conversely, with no
observed effects on cardiac dimension or function.15 Overex-
pression of ACE2 by local delivery of lentivirus in the hearts
of spontaneously hypertensive rats attenuated high blood
pressure (BP) and perivascular fibrosis, reduced left ventric-
ular (LV) wall thickness, and increased LV end diastolic and
end systolic diameters.16 Conversely, transgenic overexpres-
sion of ACE2 in murine myocardium resulted in mild
interstitial fibrosis and conduction disturbances leading to
ventricular fibrillation, arrest, and sudden death.17
Gene delivery is a powerful approach to attenuate patho-
physiological events.18 Recently, adeno-associated viruses
(AAVs), in particular, AAV 6, 8, and 9, have emerged as
promising cardiac gene transfer vectors.19–21 Here, we as-
sessed the therapeutic potential of sustained overexpression
of ACE2 on cardiac structure and function in stroke-prone
spontaneously hypertensive rats (SHRSPs), an established
recognized model of cardiovascular disease with genetic
predisposition to essential hypertension and stroke sensi-
tivity.22 Moreover, SHRSPs develop concentric LV hyper-
trophy23 in response to BP elevation23 that is evident at 12
weeks of age24 and also display endothelial dysfunc-
tion.25,26 It is considered a valuable model because patho-
physiological similarities to human disease exists, such as
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local factors for stroke,27 and male SHRSPs maintain a
higher BP than females.
Methods
These studies were approved by the home office according to regula-
tions regarding experiments with animals in the United Kingdom.
Recombinant AAV6 and Recombinant
AAV9 Vector Biodistribution and
Transduction Efficiencies
Male 6-week-old SHRSPs were administered a single IV injection of
recombinant AAV6 (rAAV6):CMVlacZ (21011, 1.51012, and
31012 viral particles [VP] per rat) in the presence or absence of
recombinant human vascular endothelial growth factor (VEGF)-165
(20 g/100 g weight) or rAAV9:CMVlacZ at identical doses under
general anesthesia (2% isoflurane, vol/vol). Two weeks postdelivery,
DNA was extracted using the QIAmp DNA Mini kit (Qiagen).
Real-time PCR was used to quantify vector genome particle number in
tissue extracts. SyBr Green PCR core reagents kit (Applied Biosystems)
with 200 nmol/L lacZ primers, forward (5ATCTGACCACCAGC-
GAAATGG3) and reverse (5CATCAGCAGGTGTATCTGCCG3)
amplified DNA under the following conditions: 95°C, 10 minutes;
95°C, 15 seconds; 60°C, 1 minute (50 cycles); 95°C, 15 seconds; 60°C,
15 seconds; and 95°C, 15 seconds. To assess -galactosidase expres-
sion, 6-m sections were blocked in 20% swine serum before 1-hour
incubation with anti–-galactosidase antibody (MP Biomedicals). Sec-
tions were incubated with swine–anti-rabbit FITC antibody. For tissue
and whole-limb staining, tissues were fixed in 2% paraformaldehyde
before incubation in 5-bromo-4-chloro-3-indolyl -D-galactoside stain
(77 mmol/L of Na2HPO4, 23 mmol/L of NaH2PO4, 1.3 mmol/L of
MgCl2, 3 mmol/L of K4Fe[CN]6, and 0.05% [vol/vol] of 20 mg/mL
5-bromo-4-chloro-3-indolyl -D-galactoside).
Assessment of Systolic BP
Four groups of animals (n6 per group) were included in the
rAAV6:ACE2 overexpression study: PBS, enalapril, rAAV6:human
placental alkaline phosphatase (control vector, as characterized previ-
ously by Odom et al28), and rAAV6:ACE2 (ACE2 cDNA was a kind
gift from Mohan Raizada). Male 8-week-old SHRSPs received 31012
vp of either rAAV6:human placental alkaline phosphatase (hPLAP) or
rAAV6:ACE2. Control animals were infused with 200 L of PBS, and
enalapril was supplied in the drinking water at 0.1 mg/mL. Systolic BP
monitoring was carried out weekly by computerized tail-cuff
plethysmography.24
Assessment of Cardiac Structure and Function
by Echocardiography
Transthoracic echocardiography was performed using an Acuson
Sequoia c512 ultrasound system with a 15-MHz linear array trans-
ducer. 2-D guided M-mode images at a 2-mm depth were recorded
at the tip of papillary muscles. Posterior and anterior wall thicknesses
of the LV chamber and its diameter during systole and diastole were
measured in short-axis view using leading edge-to-leading edge
convention. All of the parameters were measured over 3 consecutive
cardiac cycles. Ejection fraction was defined as follows: ejection
fraction[(LVEDVLVESV)/LVESD100], where LVEDV is LV
end diastolic volume, LVESV is LV end systolic volume, and LVESD
is LV end systolic diameter. Fractional shortening was derived as
follows: fractional shortening[(LVEDDLVESD)/LVEDD100],
where LVEDD is LV end diastolic diameter. Cardiac output was
derived as follows: cardiac output[(ESVEDV)HR], where ESV is
end systolic volume, EDV is end diastolic volume, and HR is heart rate.
Histological Analysis Postmortem
Formalin-fixed, paraffin-embedded tissue sections (6 m) were
deparaffinized and rehydrated through alcohol and stained with
hematoxylin and eosin. For ACE2, sections were incubated with
rabbit anti-ACE2 antibody or matched rabbit IgG nonimmune
control (Dako) then detected with biotinylated universal secondary
antibodies (1:200), ABC kit, and standard diaminobenzidine stain-
ing. For immunofluorescence, heart sections were dual stained with
ACE2 and -sarcomeric actin and detected with goat antirabbit FITC
(green) and goat antimouse Alexa 633 (red), respectively. For
Picrosirius Red, sections were incubated in Sirius Red F3B (0.1%
wt/vol saturated picric acid), washed in 0.01 N HCl, and distilled
H2O. Masson’s trichrome stain kit (Sigma) was used. For quantifi-
cation of staining, pixel intensity was measured using Image Pro-
Plus software using methods described previously.29
Statistical Analysis
Comparisons were made using 1-way ANOVA. Statistical analysis
was performed in Prism version 4.0 (Graph Pad Software). For all of
the tests, P0.05 is statistically significant following Bonferroni or
Tukey’s posthoc analysis, and results represent mean values and
SEM of the data. Cell measurements were analyzed using the
Student t test.
Results
In Vitro Assessment of Myocyte Structure
We first assessed the effects of ACE2 overexpression on the
structure of isolated primary rabbit myocytes. Adenovirus-
mediated gene transfer was used in vitro, because rAAV6
does not transduce myocytes in vitro and induce transgene
expression in the necessary time frame because of the
requirement for second-strand synthesis. ACE2 was effi-
ciently expressed by Ad5 in isolated rabbit myocytes and
resulted in a marked increase in cell hypertrophy (Figure S1A
through S1C, available in the online data supplement at
http://hyper.ahajournals.org).
rAAV6 and rAAV9 Vector Biodistribution and
Transduction Profiles in SHRSPs After
Intravascular Delivery
We determined the capacity of rAAV6 and rAAV9 vectors to
transduce the SHRSP heart after a single systemic injection.
Both vectors were efficient, and rAAV6-mediated gene
transfer was not modified by VEGF coadministration (Figure
1A and 1B). Levels of gene expression mediated by rAAV6
in mice had previously been found to be enhanced by VEGF
coadministration.30 Biodistribution studies were carried out
(Figure S2), and vector genomes were quantified by TaqMan
and revealed marked differences in vector genome accumu-
lation (Figure 1C). Furthermore, biodistribution of rAAV9-
packaged genomes to the kidney was far higher than rAAV6.
We, therefore, proceeded with rAAV6 for delivery of ACE2
to the myocardium of SHRSPs in vivo.
Effect on BP
To be packaged into rAAV6 vectors, the ACE2 gene was
cloned into an AAV shuttle plasmid and tested for functional
expression of the ACE2 gene in COS7 cells (Figure S3). Male
rats were injected with rAAV6:ACE2, control vectors, or
PBS at 8 weeks of age. A previous study indicated a
potentially beneficial effect of ACE2 overexpression on BP.16
We, therefore, analyzed BP after in vivo ACE2 gene transfer.
Enalapril treatment was included as a positive control for BP
measurements. PBS and rAAV6:hPLAP control animals
showed an equivalent increase in BP over time, characteristic
of SHRSP (Figure S4). This rise in systolic BP was signifi-
cantly attenuated by enalapril and by ACE2 overexpression
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(P0.001). The effects of ACE2 overexpression were espe-
cially evident at later time points after injection (Figure S4).
Effect of ACE2 Overexpression on In Vivo
Cardiac Function
Our principle aim was to document the effect of long-term
ACE2 overexpression on cardiac function during the estab-
lishment of hypertension and LV hypertrophy in the SHRSP,
which is evident at 12 weeks of age.24 Cardiac function was
monitored by echocardiography over the following 11 weeks.
LV M-mode echocardiography demonstrated a change in LV
diameter and reduction in wall thickness at 4, 8, and 11 weeks
postinfusion with reduced systolic function in the rAAV6:ACE2
vector–infused animals compared with PBS, enalapril, and
rAAV6:hPLAP vector–infused rats (Figure 2A). M-mode im-
ages were used to define wall thicknesses and internal diameters
at systole and diastole. Rats treated with rAAV6:ACE2 exhib-
ited a significant (28%) reduction in ejection fraction and also in
fractional shortening compared with controls (Table S1 and
Figure 2B and 2C). As expected, cardiac output increased with
age and body mass in control SHRSPs (Table S1 and Figure
2D). However, no change in cardiac output occurred in
rAAV6:ACE2-treated rats (Figure 2D). Furthermore, systolic
BP/end systolic volume ratio demonstrated that the
rAAV6:ACE2-treated SHRSP showed decreased LV perfor-
mance (Figure 2E). Interventricular septal wall thickness de-
creased by 14% in the rAAV6:ACE2 group. There was minimal
effect on wall thickness in the rAAV6:hPLAP and PBS groups,
and LV mass index did not significantly differ between groups
(Figure S5 and Table S1). Echocardiography studies, therefore,
revealed that ACE2 overexpression leads to a significant reduc-
tion in cardiac function compared with control groups.
Histological Evaluation of Cardiac Structure
Sustained overexpression of ACE2 in rats receiving
rAAV6:ACE2 was confirmed at 11 weeks postinjection
(Figure 3A). ACE2 overexpression in the heart was colocal-
ized with -sarcomeric actin expression, confirming that
ACE2 overexpression occurred selectively in cardiac myo-
cytes (Figure 3B). ACE2 mRNA was also shown to be
upregulated in the hearts of rAAV6:ACE2-treated animals in
comparison with rAAV6:hPLAP controls (Figure S6). Clear
evidence of cardiac dysregulation in ACE2-expressing hearts
was observed with irregular myocyte shape (Figure 3C). The
effect of ACE2 on cardiac fibrosis was assessed by Picro-
sirius Red (Figure 3C) and Masson’s trichrome stain (Figure
3C). Myocardial interstitial fibrosis was only observed in the
ACE2-expressing SHRSPs (Figure 3C), correlating with the
increased expression of collagen I and III in the hearts of
rAAV6:ACE2-transduced rats only (Figure S7A and S7B).
Expression of gap junction protein connexin 43 was detected
between myocytes in all of the groups (Figure 3C). The
pattern of connexin 43 staining confirmed the disrupted
myocardial organization present in the rAAV6:ACE2-infused
animals that was apparent in the hematoxylin and eosin
sections (Figure 3C). Endothelial staining with rat endothelial
cell marker RECA-1 revealed no obvious evidence of in-
creased angiogenesis in ACE2-treated rats (Figure 3C). Al-
though expression of Ang II was not seen to alter signifi-
cantly between groups, Ang 1-7 expression was significantly
increased in the rAAV6:ACE2-transduced group (Figures
4A, 4B, S7A, and S7B). Collagen I and III expression levels
were both significantly increased in the rAAV6:ACE2-
transduced group (Figures 4C, 4D, S7C, and S7D). No
evidence of increased cardiac apoptosis was found in the
hearts of rAAV6:ACE2-transduced animals at the 3-month
time point (Figure S8). In assessment of ACE and ACE2
activity in heart lysates from rAAV6:ACE2-transduced ani-
mals, ACE2 activity was greater than ACE activity, and both
were blocked by incubation with their specific inhibitors
(data not shown).
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Figure 1. Transduction of cardiac tissue by rAAV6 and rAAV9
vectors. SHRSPs were infused with 3 different doses of
rAAV6:CMVlacZ or rAAV9:CMVlacZ (11011 vp, 11012 vp, or
31012 vp). A, Transverse sections of heart tissue fixed and
stained for -galactosidase expression en face were taken 14
days postdelivery of rAAV6, rAAV6VEGF, or rAAV9 vectors. B,
Immunofluorescent detection of -galactosidase expression with
nuclear counterstain DAPI, in heart sections from rAAV6 and
rAAV9 vector-transduced animals and PBS-infused control ani-
mal. Scale bar50 m. C, Total DNA was extracted from heart,
kidney, tibialis anterior, and triceps brachii, and quantitative
PCR was performed using lacZ primers. Data are plotted as the
mean quantity of viral particles in each tissue analyzed. The 3
bars for each tissue with each virus represent the 3 different
doses.
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Global Gene Expression Profiling
To assess transcriptional activity in the hearts of animals
overexpressing ACE2, we performed gene expression profil-
ing using Illumina expression arrays on animals terminated at
4 weeks postgene transfer. Microarray analysis revealed
activation of a profibrotic phenotype at the transcriptional
level in ACE2 animals. Fibrosis-associated genes, including
collagen type III1, fibronectin 1, and lysyl oxidase, were
upregulated (Table S2 and Figure S9). Furthermore, genes
implicated in the maintenance of cardiac function, including
apelin, myosin heavy chain 11, and GATA binding protein 6,
were found to be downregulated (Table S2 and Figure S9).
The regulation of integrin 2, fibronectin 1, and myosin
heavy chain 11 was assessed in the hearts of rAAV6:ACE2-
transduced SHRSPs in comparison with rAAV6:hPLAP-
transduced SHRSPs (Figure S10A through S10C). Gene
expression data correlated with the pathway shown in Figure
S9. These data confirm the activation of transcriptional
pathways defining profibrotic effects mediated by myocardial
ACE2 delivery in vivo.
Discussion
In the present study, we demonstrate that efficient and
sustained (11-week) rAAV6-mediated ACE2 overexpression
in myocardium of SHRSPs exerts detrimental effects on
cardiac structure and function while lowering BP. Myocardial
changes were characterized by morphological adaptations
including severe myocardial interstitial and perivascular fi-
brosis, an increase in collagen content, and abnormal myo-
cardial organization. The effects of ACE2 overexpression
were presumed to be a direct effect on cardiomyocytes as
rAAV6 mediates selective gene delivery to cardiomyocytes,
confirmed by biodistribution studies and ACE2 expression
colocalization studies. However, a disruption in the commu-
nication between myocytes and cardiac fibroblasts cannot be
ruled out as a potential interaction pertinent to the develop-
ment of the observed phenotype.
Cardiomyocytes could not be isolated from the hearts of
rAAV6:ACE2-transduced SHRSPs to assess hypertrophy at
the single-cell level, because the degree of fibrosis made the
process of isolation too severe for myocyte survival. How-
ever, in vitro studies confirmed that ACE2 overexpression
leads to cardiomyocyte hypertrophy. The pivotal role of Ang
II in hypertension and LV hypertrophy is well documented.
Studies in ACE2-deficient mice15 showed an increase in
systolic BP and elevated plasma levels of Ang II, indicating
that ACE2 is key in the metabolism of Ang II. At present,
however, the role of ACE2 in the renin-Ang system remains
ambiguous. Previous ACE2 intervention studies in mice or
rats16 have shown conflicting results. Crackower et al14
proposed ACE2 as an essential regulator of heart function.
The loss of ACE2 in mice resulted in severe cardiac contrac-
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Figure 2. Assessment of cardiac function by echocardiography. Representative traces of M-mode echocardiography at preinfusion and
4, 8, and 11 weeks postinfusion in the 4 experimental groups (A). An ECG trace can be seen along the top of the images. Images from
echocardiography carried out at preinfusion and 11-week postinfusion time points were used to calculate (B) percentage change in
ejection fraction, (C) change in percentage of fractional shortening, (D) percentage of change in cardiac output, and (E) percentage of
change in SB pressure/end systolic volume ratio. *P0.05 by ANOVA and Tukey’s posthoc analysis.
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tility defects and an increase in Ang II levels, indicating that
ACE2 controls levels of Ang II in vivo.14 In a separate study,
ACE2 gene transfer resulted in significant attenuation of high
BP and cardiac fibrosis in the spontaneously hypertensive
rat.16 However, Donoghue et al17 showed that transgenic mice
with increased cardiac ACE2 expression displayed a high
incidence of sudden death. In the present study, transduction
of cardiomyocytes with both low and high doses of
Ad5:ACE2 led to an increase in cell volume. Recently, it has
been shown that ACE2 overexpression, followed by perma-
nent coronary artery ligation in rats, resulted in cardiac
function preservation.31 The BP data in this present study
correlate with that of studies in which ACE2 was overex-
pressed via lentiviral vector delivery.16 However, it is un-
likely to have occurred via the same mechanism. Using
lentiviral vectors,16 expression of ACE2 after intracardiac
injection was shown to occur in the kidney through systemic
leakage of the vector, whereas the biodistribution patterns
of our vector show no evidence of substantial expression in
the kidney. Therefore, attenuation of high BP in the
spontaneously hypertensive rat could be because of bene-
ficial effects of ACE2 acting directly to metabolize Ang II
into Ang 1-7 in the kidney. The high BP attenuation in the
present study could be explained by a beneficial effect of
ACE2 acting on the peripheral circulation, because the
expression of ACE2 in our study is not limited to the
myocardium. This effect could be mediated either as an
effect of activation of the Ang 1-7 Mas receptor, which
mediates endothelial NO synthase activation and, thus, NO
release,32 or indirectly as a consequence of reduced Ang II
levels, because Ang II has been shown to activate
NAD(P)H oxidases, resulting in reactive oxygen species
production, which inactivates NO.33,34 However, severe
cardiac dysfunction and fibrosis may have lowered BP as
a result of diastolic and systolic abnormalities generating
cardiac decompensation. Cardiac dysfunction is present
from 4 weeks postinfusion, whereas significance in BP
differences occurs from 7 weeks postinfusion, suggesting
that the underlying cardiac dysfunction precedes the low-
ered BP.
A
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Figure 3. Cardiac histological analysis.
Histological analysis was carried out on
heart sections at termination at 11-
weeks postinfusion (n4). A, Immunohis-
tochemistry with an anti-ACE2 antibody.
Scale bar100 m; magnification, 40.
B, Dual staining of heart sections with
ACE2 and -smooth muscle actin. (C)
Hematoxylin and eosin staining in all
groups. Scale bar100 m; magnifica-
tion, 40. Heart sections were analyzed
for fibrosis and collagen content by
Picrosirius Red staining. Scale
bar100 m; magnification, 25.
Masson’s trichrome staining. Scale
bar30 m; magnification, 20. Con-
nexin 43 staining and RECA-1 staining.
Scale bar100 m; magnification, 40.
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In the study most akin to that described here, local cardiac
delivery of a lentiviral vector overexpressing ACE2 resulted
in transduction levels of 50% in some areas of the myocar-
dium but to 5% in other areas.16 Although studies using
lentiviral vectors reported reduced BP and beneficial effects
on cardiac fibrosis, it is plausible that ACE2 expression levels
were not as high as in the present study. Thus, lower ACE2
levels may produce cardioprotective effects while avoiding
the induction of detrimental effects on the heart. Transgene
dose effects are supported by the occurrence of sudden death
earlier in the high ACE2-expressing transgenic mouse line
than in the lower-expressing line.17
Onset of transgene expression from AAV6 in rat has been
reported to be evident from 1 week postgene delivery,
significantly increasing by 4 weeks and maximal by 12 weeks
postgene delivery.35 The temporal profile of rAAV6:ACE2
expression thus correlates with the echocardiography data in
the present study, with deterioration of cardiac function being
visible at 4 weeks postinfusion and greatest at the end point
of 11 weeks postinfusion.
The hearts of the rAAV6:ACE2-treated animals in the
present study showed a reduction in ejection fraction and
fractional shortening, a decrease in interventricular wall
thickness, a decrease in systolic BP/end systolic volume ratio,
and no increase in cardiac output overtime, along with
histological evidence of severe fibrosis. All of these pheno-
types are consistent with severe cardiac dysfunction progress-
ing toward heart failure. This is in agreement with the
transgenic mouse study, which also found that overexpression
of ACE2 resulted in profound cardiac dysfunction and mild
cardiac fibrosis.17 Cardiac fibrosis is a marker of cardiac
failure and contributes to ventricular wall stiffness, impairing
cardiac relaxation resulting in impaired ventricular filling and
abnormal diastolic function.36–38 The pathogenesis of heart
failure inevitably proceeds to dilated cardiomyopathy, in
which heart chambers become markedly enlarged and con-
tractile function deteriorates. In early stages, cardiac enlarge-
ment is an adaptive process to maintain cardiac output.
However, as the heart overcompensates for declining systolic
performance, dilation becomes a pathological process. Dila-
tion in the present study, along with decreased wall thickness,
would account for the lack of change in LV mass index in the
ACE2-transduced SHRSP.
Perspectives
In conclusion, our data demonstrate the development of
severe cardiac abnormalities associated with sustained ACE2
overexpression in vivo. Increased expression may result in
loss of function of cardioprotective mechanisms. Additional
work should address the extent to which these effects are
correlated to the ACE2 expression levels to determine
whether beneficial effects can be obtained with reduced
expression levels or whether the increased expression of
ACE2 at any level is deleterious for cardiac morphology and
function.
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Supplementary Methods 
 
In Vitro assessment of myocyte structure 
Adenoviral infection of H9c2 cells, grown in supplemented EMEM, was performed with 
either Ad5:ACE2 or Ad5:LacZ at various multiplicity of infection (MOI). For primary 
myocytes, New Zealand White rabbits (2-2.5kg) were euthanized and hearts removed and 
perfused retrogradely (25mlmin-1, 370C) with a nominally Ca2+ free Krebs-Henseleit 
solution supplemented with 0.6mgml-1 collagenase and 0.1mgml-1 protease for 6 minutes. 
Myocytes were counted and adenoviral infection performed during seeding at 3x104 
cells/dish with either Ad5:ACE2 or Ad5:LacZ. Myocytes were cultured in supplemented 
M199 medium (Sigma) for 48 hours. Cell volume was calculated using a graticule 
(n=50). 
ACE and ACE2 Activity Assay 
ACE and ACE2 activity were determined using an assay based on the use of Fluorogenic 
Peptide Substrate VI (FPS VI) (R&D Systems, Minneapolis, USA). ACE and ACE2 
cleave an amide bond between the fluorescent group and the quencher group (Pro and 
Lys), resulting in an increase in fluorescence in the presence of ACE and ACE2 activity 
at excitation and emission spectra of 320 and 405 nm, respectively. Briefly, heart were 
lysed using lysis buffer (75 mM Tris pH 7.5, 1 M NaCl, and 0.5 µM ZnCl2) and the 
protein content determined by BCA. Samples were normalised to an arbitrary quantity 
and made up to 50 µl. To the samples the following was added; 100 µM FPS VI, 10 µM 
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ACE inhibitor captopril and reaction buffer (1 M NaCl, 75 mM Tris and 0.5 mM ZnCl, 
pH 7.5) in a final volume of 100 µl.  
 
To determine specific ACE2 activity, the experiment was also carried out in the presence 
of 100 µM ACE2 inhibitor DX600 (Phoenix Pharmaceuticals, Inc, California, USA). 
Fluorescence was monitored every 50 seconds for 2500 seconds using a 
spectrophotometer (Spectramax, Molecular Devices). 
 
Histological Analysis 
Formalin-fixed paraffin-embedded tissue sections (6µm) were sequentially deparaffinised 
and rehydrated through an alcohol gradient. For collagen 1, collagen III, Ang II and Ang 
1-7 expression analysis, sections were incubated with relevant antibody or matched rabbit 
IgG nonimmune control (Dako, Denmark) followed by detection with biotinylated 
universal secondary antibody (1/200), ABC Kit and standard diaminobenzidine staining. 
Sections were counterstained with haematoxylin.  
 
Taqman gene expression analysis 
Total RNA was isolated from heart tissue at termination (4 weeks post-infusion) 
following treatment with rAAV6:hPLAP or rAAV6:ACE2. cDNA was synthesised using 
a QPCR cDNA synthesis kit (Stratagene, CA, USA) as per manufacturer’s instructions.  
Expression of ACE2 was confirmed by Taqman™ Q-RTPCR using an ACE2 taqman 
gene expression assay (Applied Biosystems). Probes for integrin beta 2 (ITB2), 
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fibronectin-1 (FN1) and myosin heavy chain 11 (MYH11) were used to assess regulation 
of the relevant genes. 
 
Tunel assay 
Formalin-fixed paraffin-embedded tissue sections (6 µm) were sequentially 
deparaffinised and rehydrated through an alcohol gradient. Sections were digested in 5 
µg/ml proteinase K at room temperature for 15 minutes then incubated with reaction 
mixture (0.01mM dATP, 0.01mM biotin-16-dUTP, 50U Tdt) for 1 hour at 37 ºC. 
Endogenous peroxidase was blocked in 3% H2O2 before standard diaminobenzidine 
staining and haematoxylin counterstaining was carried out. 
Illumina Gene Expression Profiling 
2 groups of animals (n=6) were included in the rAAV6:ACE2 overexpression study. 
Male 8 week old SHRSP received 3×1012 vp of either rAAV6:hPLAP or rAAV6:ACE2 
and hearts were excised 4-weeks post-infusion. Total RNA from heart samples was 
isolated using RNA mini kit from Qiagen according to the manufacturers instructions 
(Qiagen GMbH, Germany). The quality of total RNA was checked using the total RNA 
Nano chip assay on an Agilent 2100 Bioanalyzer (Agilent Technologies, Germany). RNA 
concentrations were determined using the NanoDrop spectrophotometer (Labtech 
International, U.K.). 
Whole-genome-gene expression was assessed using a direct hybridisation approach. 
Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s 
recommended sample labelling procedure. Total RNA isolated from tissue underwent a 
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single round of in vitro (IVT) transcription using the TotalPrepTM RNA Labeling Kit 
(Ambion, Texas). 500ng of total RNA was used for complementary DNA synthesis, 
followed by an amplification/labelling step to synthesize biotin-labeled cRNA. Purified 
cRNA was quality controlled on an Agilent 2100 Bioanalyser and spectrophotometrically 
quantified.  
The labelled sample was then hybridised, washed and stained to each BeadChip. The 
focused Sentrix Illumina Beadchips, comprising 12 microarrays were scanned on an 
Illumina BeadArray Reader at a wavelength of 532nm and resolution of less than 
1micron. Data was captured using Beadscan vers3.5.3.1 and analysed with Beadstudio 
3.1.1.0 software (Illumina Inc, San Diego). The Bead arrays contained a 50mer gene-
specific probe to a 29mer address oligo which were in turn randomly assembled on each 
array containing > 1.6 million pits and generating an average 30 fold redundancy for each 
sequence represented. The 29-base address was used to map and decode the array, while 
the probe was used to quantify gene expression levels of transcripts. The RatRef-12 
expression BeadChip contained approx. 22,000 probes per array, as selected from the 
National Centre for Biotechnology Information Reference Sequence database. 
In addition to the gene-specific beads, each array also contained control beads (>1000), 
which allowed all steps in the process to be monitored for sample quality, labelling 
success rate, hybridisation stringency and signal generation. Illumina Beadstudio 
software also reported the performance of controls.  
Quality controlled Illumina microarrays were normalised using the rank invariant 
algorithm and the resulting data further analysed using Ingenuity Pathway analysis.  
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Data was submitted to the ArrayExpress database, accession number E-TABM-613.
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Table S1. Echocardiography findings 
 
 
EF, ejection fraction; FS, fractional shortening; CO, cardiac output; LVMI, left ventricular mass index; RWT, relative wall thickness; IVSWT, 
interventricular septal wall thickness; SBP:ESV, ratio of systolic blood pressure to end systolic volume; HR, heart rate.*p<0.05 rAAV6:ACE2 
vs. PBS, Enalapril and rAAV6:hPLAP. 
Group 
 
Week %EF %FS CO (ml/min) LVMI 
(mg/g) 
RWT % IVSWT SBP:ESV HR (b/min) 
PBS 0 88.0 ± 1.5 53.0 ± 2.3 168.6 ± 1.6 2.48 ± 0.1 0.54 ± 0.02 45.0 ± 1.9 2314 ± 433 405.8 ± 1.9 
 11 81.3 ± 1.1 50.8 ± 4.1 234.5 ± 18.5 2.96 ± 0.1 0.60 ± 0.01 44.3 ± 3.1 3600 ± 382 375.7 ± 4.0 
rAAV6:hPLAP 0 84.5 ± 1.3 49.0 ± 1.7 183.5 ± 7.8 2.51 ± 0.1 0.55 ± 0.02 41.5 ± 3.5 1965 ± 126 428.9 ± 19.9 
 11 82.3 ± 1.3 51.3 ± 2.5 233.2 ± 17.8 2.86 ± 0.1 0.60 ± 0.03 43.3 ± 3.5 2842 ± 458 377.2 ± 7.5 
rAAV6:ACE2 0 89.0 ± 1.7 55.0 ± 3.2 205.8 ± 2.2 2.84 ± 0.3 0.49 ± 0.01 48.7 ± 1.8 2277 ± 341 393.4 ± 2.6 
 11  62.0 ± 2.7* 34.3 ± 4.9* 204.9 ± 17.6* 2.62 ± 0.2 0.49 ± 0.01 33.7 ± 4.4* 582   ± 57* 372.2 ± 9.2 
Enalapril 0 84.3 ± 1.3 51.5 ± 0.3 179.1 ± 6.7 2.37 ± 0.1 0.52 ± 0.02 47.5 ± 1.9 2343  ± 159 385 ± 8.7 
 11 80.5 ± 2.1 56.0 ± 1.5 231.3 ±  10.1 2.31 ± 0.1 0.57  ± 0.01 42.25 ± 1.3 3003 ± 257 411 ± 4.0 
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Table S2. Global Gene Expression Profiling – Illumina microarray analysis data 
revealed altered expression of a range of genes. This table lists fold changes and 
difference (diff.) scores of 25 of the most up-regulated and down-regulated genes for 
rAAV6:ACE2 vs rAAV6:hPLAP. 
 
 
 
 
 
 
  
RGD15497
THBD 
SYPL 
APLN 
LOC498122
DLST 
MYOM2 
SLC9A3R2
CAT 
NOV 
RGD13049
LOC686087
LOC497785
HRC 
ES2 
KCNE1 
FGF12 
MGC72973
DSCR1L1
LOC498920
CARD9 
RGD15649
PENK-RS
NGRN 
MYH11 
TargetID 
 
0.77-18.715 25 
0.75-18.817 
0.78-19.134 
0.63-19.134 
0.56-19.138  
0.76-19.417 
0.78-19.702 
0.6 -20.508  
0.75-20.508 
0.56-20.963 
0.77-21.377 31 
0.75-21.412  
0.75-21.901  
0.77-21.992 
0.58-22.311 
0.42-23.045 
0.7 -23.251 
0.66-26.339  
0.76-26.339  
0.69-26.808  
0.72-30.291 
0.69-34.341 24 
0.66-35.57  
0.51-36.449 
0.68-44.402 
Fold 
Change 
 
Treated 
Diff.Score 
 
2.3340.818 TIMP1
2.16340.818 THBS4
2.08340.818 SPP1
2.1340.818 POSTN
1.99340.818 LTBP2
6.41340.818 LOC498335
1.93340.818 LCP1
2.05340.818 CXCL16
1.93340.818 CTSS
2.23340.818 CD68
1.76114.972 FN1
2.45110.579 RT1-DB1
2.28106.825 DCIR3
1.69104.136 SSG1
1.97103.278 SPON1
1.8498.696 LOC498279
1.8894.602 RBP1
3.0789.544 MSR2
1.7386.205 MAFB
2.8385.106 APOBEC1
1.6884.997 CCL2
2.9584.348 RT1-BA
1.7683.903 LR8
1.9383.869 GM2A
3.0381.292 GC105649
Fold 
Change 
Treated  
Diff.Score 
 
TargetID 
 
M
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Figure S1 In vitro effects of ACE2 overexpression on cell hypertrophy
(A) Western blot analysis of extracts from infected H9c2 cells to show ACE2 overexpression 
by adenovirus-mediated gene delivery. Cells were infected with a MOI of 50, 100 and 150 
pfu/cell. (B) Immunocytochemical localisation of ACE2 to the cell surface in H9c2 cells (C) 
Isolated single cells were transduced with either Ad5:ACE2 or Ad:5LacZ and cell 
dimensions quantified. Transduction with Ad5:ACE2 resulted in significantly increased cell 
volume of isolated rabbit myocytes (n=50/group). * p<0.05 vs control and Ad:5LacZ 
infected cells.
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A B C
Figure S2 rAAV6:CMVlacZ gene transfer to non-cardiac tissue.
rAAV6:CMVlacZ vectors (3x1012
 
vp/rat) were infused into 6 week old SHRSP rats (n=1). (A) 
Skeletal muscle, (B) liver and (C) kidney were stained for β-galactosidase after 14 days. 
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Figure S3 Confirmation of functional ACE2
Cells were transfected with pAAV-ACE2. 48 hours after lipofectamine transfection, cells were 
harvested and lysed. (A) Cell lysates were subjected to western immunoblotting and detected 
with an anti-ACE2 antibody on a 12% gel under reducing conditions. (B) ACE2 activity was 
measured in the presence of captopril and DX600. 
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Figure S4 Effect of overexpression of ACE2 on systolic blood pressure 
Animals were infused with either rAAV6:hPLAP, rAAV6:ACE2, PBS or treated with Enalapril. 
Systolic blood pressure was measured weekly by tail cuff. Data are presented as mean ± SE. * 
p<0.001 rAAV6:ACE2 and Enalapril vs. PBS and rAAV6:hPLAP, as determined by ANOVA 
analysis and Bonferroni test. 
 at GLASGOW UNIV LIB on August 10, 2010 hyper.ahajournals.orgDownloaded from 
-20
-10
0
10
PBS
rAAV6:hPLAP
rAAV6:ACE2
Enalapril
%
 C
ha
ng
e 
in
 IV
SW
 T
hi
ck
ne
ss
*
Figure S5 Interventricular septal wall thickness
Echocardiography was carried out pre-infusion and at 11 weeks post-infusion on 
rAAV6:hPLAP, PBS, Enalapril and rAAV6:ACE2 treated animals. Images were used to 
calculate % change in interventricular septal wall thickness. *p<0.05 by ANOVA and 
Tukey’s post hoc analysis. 
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Figure S6 Quantification of ACE2 
Total RNA was isolated from heart tissue at termination at (A) 4 weeks post-infusion and (B) 
11 weeks post-infusion following treatment with rAAV6:hPLAP or rAAV6:ACE2 and 
taqman gene expression analysis performed to quantify ACE2 mRNA. Data are presented as 
fold change (RQ). *p<0.05 vs rAAV6:hPLAP by students t-test.
*
*
 at GLASGOW UNIV LIB on August 10, 2010 hyper.ahajournals.orgDownloaded from 
rAAV6:ACE2Enalapril rAAV6:hPLAPPBS
A
B
C
D
Figure S7 Histological Analysis
Histological analysis was carried out on heart sections at termination (n=4). (A) Immunohistochemistry 
with (A) an anti-Collagen I antibody, (B) anti-collagen III antibody, (C) anti-Ang 1-7 antibody and (D) anti- 
Ang II antibody. Scale bar = 30µm, magnification × 20. 
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Figure S8 Assessment of cardiac apoptosis
Terminal deoxynucleotidyl transferase dUTP nick end labeling (Tunel) was carried 
out on heart sections taken at termination from PBS, Enalapril, rAAV6:hPLAP and 
rAAV6:ACE2 transduced animals.
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Figure S9 Gene expression profiling
Total RNA was isolated from heart tissue at termination (4 weeks post-infusion) following treatment with rAAV6:hPLAP or 
rAAV6:ACE2 and Illumina microarray analysis performed. Ingenuity pathway analysis revealed the dysregulation of a number of 
genes and pathways. The most altered pathway is shown. Red indicates gene up-regulation for rAAV6:ACE2 vs rAAV6:hPLAP, 
whilst green represents gene down-regulation for rAAV6:ACE2 vs rAAV6:hPLAP. Grey represents unchanged genes.
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Figure S10 Taqman gene expression analysis
Total RNA was isolated from heart tissue at termination (4 weeks
 
post-infusion) following 
treatment with rAAV6:hPLAP or rAAV6:ACE2 and taqman
 
gene analysis performed with
 
 
probes for (A) Integrin
 
β2 (ITB2), (B) Fibronectin
 
1 (FN1) and (C) Myosin heavy chain 11 
(MYH11). *p<0.05 vs
 
rAAV6:hPLAP by students t-test.
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